Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Narcolepsy

Narcolepsy

Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.

Sleep-Wake Cycles

Sleep-Wake Cycles

Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...

Drugs Acting on Autonomic Ganglia: Stimulants

Drugs Acting on Autonomic Ganglia: Stimulants

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Neuropsychological Tests for Detecting Prodromal DLB: A Systematic Review.

European journal of neurology·2026

Same author

Antibodies against influenza A/H1N1pdm2009 and B/Victoria strains but not A/H3N2 are increased in recent onset type 1 narcolepsy versus matched controls.

medRxiv : the preprint server for health sciences·2026

Same author

Sustained attention in dementia with Lewy bodies: a task-based fMRI study.

Frontiers in aging neuroscience·2026

Same author

Protocol for the DREAMER study: Design and methodological framework of a multicenter trial-ready cohort of individuals with isolated REM sleep without atonia.

PloS one·2026

Same author

To diagnose Narcolepsy type 1 after a negative Multiple Sleep Latency Test: the contribution of systematic hypocretin measurement.

Sleep·2026

Same author

The Italian registry for narcolepsy and central disorders of hypersomnolence (ReN&IS): Baseline clinical and diagnostic findings.

Sleep medicine·2026

Search research articles

Related Experiment Video

Updated: May 28, 2025

Polygraphic Recording Procedure for Measuring Sleep in Mice

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

Pons metabolite alterations in narcolepsy type 1.

Micaela Mitolo^1,2, Fabio Pizza^3,4, David Neil Manners^2,5

¹Department of Medicine and Surgery, University of Parma, Parma, Italy.

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

|February 14, 2025

Summary

This summary is machine-generated.

Narcolepsy type 1 (NT1) patients exhibit altered pons metabolism, specifically lower NAA/Cr and NAA/mI ratios. These metabolic changes correlate with disease severity and hypocretin-1 levels, indicating their role in NT1 pathophysiology.

Keywords:

Metabolic alterations Narcolepsy type 1 Pons Proton MR spectroscopy

More Related Videos

Simultaneous Electroencephalography, Real-time Measurement of Lactate Concentration and Optogenetic Manipulation of Neuronal Activity in the Rodent Cerebral Cortex

Simultaneous Electroencephalography, Real-time Measurement of Lactate Concentration and Optogenetic Manipulation of Neuronal Activity in the Rodent Cerebral Cortex

Published on: December 19, 2012

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking

Published on: August 6, 2013

Related Experiment Videos

Last Updated: May 28, 2025

Polygraphic Recording Procedure for Measuring Sleep in Mice

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

Simultaneous Electroencephalography, Real-time Measurement of Lactate Concentration and Optogenetic Manipulation of Neuronal Activity in the Rodent Cerebral Cortex

Simultaneous Electroencephalography, Real-time Measurement of Lactate Concentration and Optogenetic Manipulation of Neuronal Activity in the Rodent Cerebral Cortex

Published on: December 19, 2012

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking

Published on: August 6, 2013

Area of Science:

Neuroscience
Metabolic Imaging
Sleep Medicine

Background:

Narcolepsy type 1 (NT1) is a rare central nervous system disorder characterized by the loss of hypocretin/orexin (hcrt)-producing neurons.
This neuronal loss affects widespread brain and brainstem areas, leading to characteristic sleep disturbances.

Purpose of the Study:

To investigate metabolic alterations in the pons of NT1 patients using Magnetic Resonance Spectroscopy (MRS).
To explore the association between these pontine metabolic changes and clinical features of NT1.

Main Methods:

¹H MRS was performed on 21 NT1 patients and 20 healthy controls to quantify N-acetyl-aspartate (NAA), choline (Cho), and myo-inositol (mI) relative to creatine (Cr).
Clinical data, including sleepiness scales, polysomnography, Multiple Sleep Latency Test (MSLT), cerebrospinal fluid (CSF) hcrt-1 levels, and genetic markers, were collected.

Main Results:

NT1 patients showed significantly lower NAA/Cr and NAA/mI ratios in the pons compared to controls.
Pontine NAA/Cr correlated negatively with daytime sleepiness (Epworth Sleepiness Scale) and positively with CSF hcrt-1 levels.
Pontine mI/Cr and Cho/Cr ratios correlated with MSLT sleep latency, REM sleep periods, and CSF hcrt-1 levels.

Conclusions:

MRS detects significant metabolic alterations in the pons of NT1 patients.
These pontine metabolic changes are associated with both subjective and objective measures of NT1 severity.
Pontine metabolites serve as potential biomarkers for understanding NT1 pathophysiology.